• 30 Jul 2017

    SimilarWeb has raised $47M in growth equity funding
    SimilarWeb, the leading digital market intelligence company, today announced that it has raised $47M in growth equity funding.  With this investment, SimilarWeb increased its total funding to date to $112M and has evolved into one of the fastest growing SaaS companies in the world. The round was led by Viola Growth, a leading growth equity investor in Israel, in collaboration with Saban Ventures. Additional participating investors included CE Ventures, among others. More than half of the Fortune 100 rely on SimilarWeb’s market intelligence solutions, which offer industry-leading insights on over 80 million websites and three million apps across more than 190 countries.  SimilarWeb’s thousands of customers include CMOs, digital marketers, investors, strategy professionals and business analysts at the world’s leading brands, agencies, and consulting firms.   SimilarWeb’s market intelligence solutions provide essential insights on competitors, industry and audience that enable companies to capitalize on market opportunity and increase market penetration.   “We’re excited to lead the round and support SimilarWeb’s growth towards further establishing its presence as global leader in the market intelligence industry,” said Harel Beit-On, Founder and General Partner of Viola Growth. “SimilarWeb empowers some of the most notable global brands to better understand, grow, and track their digital market share, fueling the rapid adoption of SimilarWeb’s platform globally. With their proven technology, impressive team and global list of customers, the company is well positioned for accelerated growth and mass market penetration.”
  • 07 Jul 2016

    Viola Group Exit: RRMedia acquisition is completed!
    MX1 Reveals New Company Brand as a World-Leading Media Services Company
    The First Media Globalizer, Created by the Merger of SES Platform Services and RR Media, Will Present Its Full Range of Services at IBC2016
    MUNICH, GERMANY and AIRPORT CITY, ISRAEL--(Marketwired - Jul 6, 2016) - Following the leading satellite operator SES's (Euronext Paris and Luxembourg Stock Exchange: SESG) successful completion of the acquisition of RR Media and the latter's merger with SES Platform Services, MX1 is the name of the new merged global media services company. MX1 leverages the capabilities and infrastructure of both companies to offer a full suite of innovative digital video and media services. The world's first media globalizer, MX1 works with leading media businesses to transform content into the ultimate viewer experience for a global audience, amplifying the value of the world's media content.
    Bringing it all together for the first time, MX1 aims to be the new number 1 in Media eXperience. The company provides highly optimised content management and distribution services for premium content, utilising the combined global networks of the merged companies, as well as their cloud technologies, to maximise audience reach over multiple screens and increase monetisation opportunities for customers. These services include a comprehensive range of high-quality video and media solutions delivered over satellite, fibre and the internet.
    MX1 offers full continuity and enhanced services to all of SES PS's and RR Media's existing customers and partners. Together, MX1 distributes more than 1,000 TV channels, manages the playout of 440 channels and delivers syndicated content to more than 120 leading subscription VOD platforms. The new company has 16 offices worldwide and operates six global state-of-the-art media centres, enabling customers to reach billions of people around the world.
    Avi Cohen, former CEO of RR Media and newly-named CEO of MX1, said, "This is an exciting day for us as we introduce a new company to the industry and our new brand name and logo. MX1 enables new richer viewers' experiences, the widest audience reach, and new business models for broadcasters, rights holders, sports organisations and distributors. We deliver these experiences like no one else, with unrivalled expertise, an unmatched range of capabilities, proven flexibility, and an enhanced global presence. This merger allows us to scale-up on a global basis and become the world's leading media services provider, delivering next-generation digital video and media solutions to our worldwide customers. Closer to them, wherever they are, we enable them to optimise their media and deliver it to global audiences like never before."
    "MX1 brings a new kind of business to the market, serving global customers as a complete end-to-end media experience provider. We look forward to presenting our new complete global offering and the management team at IBC Amsterdam in September," continued Cohen.
    MX1 will present its full range of services at IBC2016 at the RAI Amsterdam, 9-13 September (Stand no. 1.B24).
    About MX1
    MX1, a wholly-owned subsidiary of SES (Euronext Paris and Luxembourg Stock Exchange: SESG), is a global leading media services provider. The world's first media globalizer works with leading media businesses to transform content into the ultimate viewer experience for a global audience. With more entertainment, more innovation and more impact, MX1 offers a full range of content management, delivery and value-added digital media services. Together, MX1 distributes more than 1,000 TV channels, manages the playout of 440 channels and delivers syndicated content to more than 120 leading subscription VOD platforms. The new company has 16 offices worldwide and operates six global state-of-the-art media centres, enabling customers to reach billions of people around the world. To find out more, visit and follow us on Twitter and Facebook.

  • 26 Apr 2016

    West Pharmaceutical Services, Inc. (NYSE:WST) completed a strategic investment of $8.4 million in NanoPass, a Viola Partners portfolio company
    West Makes Strategic Investment in NanoPass Technologies
    EXTON, Pa., April 25, 2016 -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced a strategic investment in NanoPass Technologies Ltd. This investment will provide West with access to NanoPass’ knowledge and expertise in the growing area of intradermal drug delivery, and future collaboration opportunities to bring new products to market. West’s strategic investment will allow Nanopass to advance its clinical development efforts, and support the launch of its microneedle-based device for intradermal delivery of vaccines and drugs.
    “We expect that advances in intradermal drug delivery will be critical to realizing the full potential of some of the pharmaceutical and biotech industry’s latest advancements in vaccine and immunotherapy treatments,” said Eric Resnick, Chief Technology Officer and Vice President, Innovation and Technology, West. “The microneedle technology developed by NanoPass complements our growing portfolio of drug delivery solutions at West, including our own Intradermal Adapter. We believe NanoPass has made great strides in this specialized area of drug delivery and we look forward to our partnership.”
    "We are delighted to enter into this strategic partnership with West, a recognized global leader in the integrated containment and delivery of injectable drugs,” said Dr. Yotam Levin, Chief Executive, NanoPass. “We share a vision of enabling new vaccines, cancer and allergy immunotherapies with our intradermal injection technology, and envision significant synergies in production, marketing and future device developments. We could not have found a more suitable partner with the global reach, capacity and related expertise to grow NanoPass to the next level."


    About NanoPass
    NanoPass is a pioneer in the development of intradermal delivery for vaccines and cancer, allergy and diabetes immunotherapy. The Company’s microneedle system, MicronJet600™ is a microneedle-based device for intradermal delivery of vaccines and drugs, which enables consistent and less painful [1,2,3] delivery of therapeutics directly into the skin. MicronJet600™ is registered for marketing in various
    territories including the US FDA 510k clearance, for use by health care professionals for intradermal delivery.
    NanoPass has one of the largest clinical databases in the industry for ID vaccination. It has supported numerous clinical studies in various fields including vaccines (seasonal and pandemic influenza, polio, zoster and others) with top pharmaceutical companies and the Centers for Disease Control and Prevention [1-6] and is supporting multiple cancer, allergy and diabetes immunotherapy studies on a global scale (Phase I to III). In many of these trials it was demonstrated that significant dose sparing (x5 -to x27) is achievable with the device [1,4,5,6]. Intradermal delivery is thought to harness the skin’s potent immune system to improve vaccines, and/or to dramatically reduce their dose while achieving equivalent effect. The company was founded by Dr. Shuki Yeshurun and is backed by prominent investors including IHCV, XT Hi Tech Investments, DPartners and Elcam Medical. For more information visit:


    About West
    West Pharmaceutical Services, Inc. is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Working by the side of its customers from concept to patient, West creates products that promote the efficiency, reliability and safety of the world's pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its customers from locations in North and South America, Europe, Asia and Australia. West's 2015 sales of $1.4 billion reflect the daily use of approximately 110 million of its components and devices, which are designed to improve the delivery of healthcare to patients around the world. For more information visit:


    1. Hung I et al. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine. 2012 Oct 5;30(45):6427-35
    2. Abhijeet A et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial. Vaccine. 2015 Nov 27;33(48):6816-22
    3. Lee H et al. Safety and efficacy of tuberculin skin testing with microneedle MicronJet600 in healthy adults. Int J Tuberc Lung Dis. 2016 Apr;20(4):500-4.
    4. Levin Y et al. Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future. Hum Vaccin Immunother. 2015;11(4):991-7.
    5. Beals C et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infect Dis. 2016 Apr 6. [Epub ahead of print]
    6. Levin Y et al. Clinical evaluation of a novel microneedle device for intradermal delivery of an influenza vaccine: Are all delivery methods the same? Vaccine. 2014 Jul 23;32(34):4249-52

    Our People


    Viola Partners is an exclusive investment fund tailored especially for private investors.

    Founded in 2000 under the name of D Partners, Viola Partners currently has three funds under management and  managed SPVs, aggregating approximately US$350 million in capital commitments, from leading international and Israeli private investors. Viola Partners is a unique investment fund created to accommodate the General Partners and other private investors, who wish to receive priority access to, and invest in and with the Viola Group, in a uniquely tailored model.





    • 2017 (1)
    • 2016 (5)
    • 2015 (13)
    • 2014 (11)
    • 2013 (3)

    Latest News

      • RR Media Reports Revenues of $33.1 Million for the Second Quarter 2015

        RR Media Reports Revenues of $33.1 Million for the Second Quarter 2015

      • RRsat posts $1.1M net income in Q3 2013


        Nov 13, 2013 (Menafn - M2 EQUITYBITES via COMTEX) --RRsat Global Communications Network Ltd RRST, a provider of comprehensive digital content management and global content distribution services to the broadcasting industry, on Tuesday reported GAAP net income of USD1.1m, or USD0.06 per diluted share, for the third quarter of 2013, ended 30 September 2013.



    12 Abba Eban Avenue
    Ackerstein Towers Bldg. D
     12th floor Herzeliya 46725 Israel
     Tel: +972 9 9720 500 
     Fax: +972 9 9720 501 


    Thanks for your interest in Viola Group!
    Did you know that we also have a blog?
    Visit Viola Notes now or subscribe to our blog updates using this form.
    Thanks for signing up!
    Don't forget to confirm your subscription (we just sent you an email).